{
  "docId": "019de070-5095-745c-b54c-b78e5ae1b904",
  "docSlug": "0dc8a543e5d2136d106b59f85712c2a9",
  "documentTitle": "Taysha | IPO Presentation Deck | 66 slides",
  "authorId": "taysha",
  "authorName": "Taysha Gene Therapies",
  "documentKindSlug": "pitchdeck",
  "documentKindLabel": "Pitch deck",
  "sourceTypeSlug": "investment_bank",
  "sourceTypeLabel": "Investment bank",
  "presentationDate": "2020-09-01 00:00:00",
  "orientation": "landscape",
  "aspectRatio": 1.7777778,
  "pageNumber": 55,
  "pageCount": 66,
  "prevPage": 54,
  "nextPage": 56,
  "slideType": "problem_statement",
  "function": "frame_problem",
  "density": "dense",
  "nDataPoints": 30,
  "notes": "Includes a bar chart of EPM2A/EPM2B cases by country and a biological process diagram showing the transition from glycogen to Lafora bodies.",
  "elementsJson": null,
  "metadataConfidence": 1,
  "imagePath": null,
  "slideHref": "/slides/019de070-5095-745c-b54c-b78e5ae1b904/55",
  "deckHref": "/decks/019de070-5095-745c-b54c-b78e5ae1b904",
  "deckJsonHref": "/decks/019de070-5095-745c-b54c-b78e5ae1b904.json",
  "deckAnchorHref": "/decks/019de070-5095-745c-b54c-b78e5ae1b904#slide-55",
  "components": [
    {
      "bbox": {
        "h": 0.35,
        "w": 0.45,
        "x": 0.52,
        "y": 0.15
      },
      "kind": "chart",
      "text": "Number of EPM2A And EPM2B Cases According To Ethnicity/Country",
      "attrs": null,
      "subkind": "bar-grouped",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "635505b5-a47f-4bfe-9080-1f0c346f2fb0",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.3,
        "w": 0.45,
        "x": 0.52,
        "y": 0.6
      },
      "kind": "diagram",
      "text": "Glycogen to Lafora body transition diagram",
      "attrs": null,
      "subkind": "process",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "27ed8ac5-95a9-42cb-ad08-24b409bd2101",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.25,
        "w": 0.4,
        "x": 0.05,
        "y": 0.65
      },
      "kind": "image",
      "text": "AAV9 gene therapy delivery mechanism",
      "attrs": null,
      "subkind": "infographic",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "e10aeeda-4af5-4bfe-83bf-2af9c2d011b6",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.3,
        "w": 0.4,
        "x": 0.05,
        "y": 0.2
      },
      "kind": "list",
      "text": "Teenage onset disease, severe neurodegenerative epilepsy\nCaused by mutations in either EPM2A (laforin) or EPM2B (malin)\nProgressive and invariably fatal, leading to death 5-10 years after onset\nThe estimated prevalence of Lafora disease is 700 patients in the US and EU",
      "attrs": null,
      "subkind": "bullet",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "d5ac7bbb-0049-4550-b724-62d4f730c726",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.1,
        "w": 0.4,
        "x": 0.05,
        "y": 0.05
      },
      "kind": "title",
      "text": "Lafora disease is a fatal disorder of glycogen metabolism",
      "attrs": null,
      "subkind": "headline",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "c5076434-f367-4023-b318-e1af6ab93842",
      "frameworkName": null,
      "frameworkSlug": null
    }
  ],
  "metrics": [],
  "tools": [],
  "frameworks": [
    {
      "name": "causal-chain",
      "slug": null,
      "matchId": "3738aa05-13d5-4819-9272-8a8b497f64c1",
      "evidence": "Diagram showing mutation leading to Lafora bodies and disease",
      "confidence": 0.8
    }
  ],
  "arcBeats": [
    {
      "to": 66,
      "from": 31,
      "beatId": "a2d2f153-e121-48a0-8c8f-2d7d544ceb56",
      "arcName": "AIDA",
      "arcSlug": "aida",
      "beatName": "Action",
      "beatSlug": "aida-action",
      "evidence": "The deck concludes with a call to action, presenting the company's plans for clinical and commercial development.",
      "position": 3,
      "confidence": 0.8,
      "parentBeatName": "Resolution",
      "parentBeatSlug": "resolution"
    }
  ],
  "loops": [],
  "imagePathAlt": null,
  "thumbSrc": null,
  "thumbSrcAlt": null,
  "locked": true
}